DailyIQ
|
Sector:Real EstateAll sectors
Last updated 1 minute ago

DOC·Healthpeak Properties, Inc.

$.
+. (+.%)
Pre-Market
High
$20.10
Open
$19.99
Market Cap
13.94B
52W High
$20.08
Low
$19.99
P. Close
$20.07
P/E
62.74
52W Low
$15.70
Fwd P/E
465.97
Mean Target
$20.72
Technical Score (1D)
100
BUY
News Sentiment
71
BULLISH
Healthpeak Properties (DOC) is experiencing significant analyst attention, with multiple firms raising price targets following strong Q1 results and an improved outlook. Morgan Stanley and RBC Capital have both reiterated Outperform ratings and raised their price targets to $20 and $21 respectively, signaling sustained confidence. Baird also raised its target to $21, maintaining an Outperform rating, citing Healthpeak's modest increase in FY26 FFO guidance. This positive analyst sentiment follows Healthpeak's Q1 adjusted FFO of $0.45 per share and an upward revision of full-year FFO guidance to $1.71-$1.75 per share, driven by strategic capital allocation including a senior housing IPO and joint venture recapitalization. The company's strong performance in outpatient medical leasing, with high occupancy and tenant retention, alongside sequential improvement in life science occupancy, underpins this optimistic outlook. Despite a prior 5-year return decline and recent share price jumps, analysts are focusing on DOC's sector positioning and portfolio against broader industry trends. The REIT's substantial cash reserves of $1.17 billion also support its sustainable 6.2% dividend yield, positioning it as an attractive option within the healthcare real estate sector. Investors should watch for continued execution on growth initiatives and any shifts in broader economic indicators that may influence real estate valuations.
Earnings Summary
Healthpeak Properties, Inc. is a U.S.-based real estate investment trust (REIT) specializing in the healthcare sector, owning and developing properties across outpatient medical, lab, and continuing care retirement community segments. As a significant player in the healthcare real estate market, Healthpeak operates within a sector influenced by demographic trends and healthcare utilization. Analyzing Healthpeak's recent earnings, the company demonstrated mixed performance in the last four reported quarters. In Q4 2025, Healthpeak reported EPS of $0.47 on revenue of $719.4 million, significantly beating the estimated EPS of $0.0572 and exceeding revenue estimates of $698.4 million. This followed a Q3 2025 where the company posted an EPS of -$0.1819 against an estimate of $0.06, and revenue of $690.3 million. Prior to this, Q2 2025 saw EPS of $0.06172 against an estimate of $0.055, with revenue at $678.5 million, and Q1 2025 reported EPS of $0.0633 against an estimate of $0.045, with revenue at $687.1 million. The trend shows an acceleration in EPS beats from Q1 2025 through Q4 2025, with a notable miss in Q3 2025, while revenue has shown a general upward trend. Historically, Healthpeak's year-over-year growth trajectory has been subject to fluctuations, particularly in EPS. The company has shown a pattern of beating analyst estimates for EPS in three of the last four reported quarters (Q1 2025, Q2 2025, Q4 2025), with Q3 2025 being a significant miss. Revenue has generally shown consistent growth, indicating operational stability even when EPS faced challenges. Recent news highlights a positive outlook from analysts, with Baird boosting Healthpeak's price target and reiterating an Outperform rating, citing Q1 results and an improved outlook, alongside a modest increase in FY26 FFO guidance. The company maintains a strong cash position of $1.17 billion, supporting its dividend yield and providing resilience amidst macroeconomic headwinds and current weakness in the lab sector. This financial strength is seen as a potential catalyst for valuation re-rating. Looking ahead, investors will be watching for Healthpeak's continued execution on its raised guidance and the ongoing impact of the Janus Living IPO on its portfolio. Key will be the company's ability to translate its strong financial position and strategic positioning into sustained revenue and EPS growth, particularly as the lab sector dynamics evolve. sector potentially drives a valuation re-rating.

EPS

EstBeatMiss
$-0.28$-0.07$0.14$0.36$0.57Q4'24Q1'25Q2'25Q3'25Q4'25
QtrEstActual+/−
Q1'26 - - -
Q4'25$0.06$0.47+721.7%
Q3'25$0.06$-0.18-403.2%
Q2'25$0.06$0.06+12.2%
Q1'25$0.04$0.06+40.7%
Q4'24$0.05$0.05-4.7%

Revenue

EstBeatMiss
$672M$686M$699M$712M$726MQ4'24Q1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$697M - -
Q4'25$698M$719M+3.0%
Q3'25 - $690M -
Q2'25 - $679M -
Q1'25 - $687M -
Q4'24 - $681M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

DOC Stock Snapshot

DOC is currently trading at $20.08, giving Healthpeak Properties, Inc. a market cap of 13.94B and a P/E ratio of 62.7. Today's range spans $19.99–$20.10, with shares opening at $19.99 and moving up $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 100/100 (BUY) with a news sentiment reading of 71/100.

Over the past year DOC has traded between $15.70 and $20.08 - the current price is +27.9% off the 52-week low and +0.0% from the high. 26 analysts cover the stock with a Hold consensus and a mean 12-month target of $20.72 (range $17.00–$29.00), implying upside of +3.2%.

The Real Estate sector has plenty of names, but DOC is one of the few right now where technical and sentiment data are both bullish. Score: 100/100 (BUY). Sentiment: bullish (71/100). Price: $20.08 (near 52-week highs). The current P/E ratio stands at 62.7. With 13.94B in market cap, this is the scale where fundamental thesis and technical setup reinforce rather than compete with each other. Annual range: $15.70–$20.08.

Earnings revision cycles in large-cap Real Estate names tend to compound: when technicals confirm a BUY thesis (100/100) and news sentiment (71/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $20.08 (near 52-week highs), DOC's position within the $15.70–$20.08 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.